Adoptive T-cell transfer in cancer immunotherapy (Q36471818)

14 August 2017

1 reference

title

Adoptive T-cell transfer in cancer immunotherapy (English)

1 reference

14 August 2017

1 reference

2

Catherine M Bollard

1 reference

14 August 2017

3

Helen E Heslop

1 reference

14 August 2017

1

Siok-Keen Tey

1 reference

14 August 2017

1 June 2006

1 reference

Immunology & Cell Biology

14 August 2017

1 reference

14 August 2017

84

1 reference

14 August 2017

3

1 reference

14 August 2017

281-289

1 reference

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

14 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Cancer/testis-associated genes: identification, expression profile, and putative function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Graft-versus-leukemia reactions in allogeneic chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

An inducible caspase 9 safety switch for T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Post-transplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Epstein-Barr virus: 40 years on

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Adoptive-cell-transfer therapy for the treatment of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Current status of genetic modification of T cells for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Targeting tumours with genetically enhanced T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Dual-specific T cells combine proliferation and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Tolerance, not immunity, crucially depends on IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

NHLBI plans for the promise of cell-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1711.2006.01441.X

10.1111/J.1440-1711.2006.01441.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16681825